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Abstract
Purpose To describe the characteristics and potential differences between focal and diffuse phenotypes of untreated chronic
central serous chorioretinopathy (cCSC).
Methods For this study, patients were divided in two groups. Focal leakage was defined as 1 Bhot spot^ of leakage, whereas
diffuse leakage was defined as either > 1 hot spot or a larger area of widespread leakage on FA. Clinical characteristics were
assessed at presentation. After Bonferroni correction, P values < 0.00125 were deemed statistically significant.
Results The focal leakage group included 68 eyes (53 males), and the diffuse leakage group included 105 eyes (88 males). Mean
best-corrected visual acuity (BCVA) was 77.1 ± 8.1 Early Treatment of Diabetic Retinopathy Study (ETDRS) letters in the focal
group and 76.0 ± 9.6 ETDRS letters in the diffuse group (p = 0.440). In the focal group, mean age was 46.9 ± 8.8 years, whereas
this was 49.7 ± 8.3 years in the diffuse group (p = 0.033). Mean central foveal thickness was 107.1 ± 21.3 μm in the focal group
and 106.2 ± 27.3 μm in the diffuse group (p = 0.818). Mean choroidal thickness was 407.5 ± 114.8 μm in the focal group and
419.1 ± 113.9 μm in the diffuse group (p = 0.578). In the focal group, subretinal fluid was present in the fellow eye in 16% of the
patients, as compared to 29% in the diffuse group (p = 0.067).
Conclusions In untreated cCSC patients with focal or diffuse leakage on FA, no marked differences in clinical characteristics
were found. Extensive choroidal abnormalities may be present in both groups, which are presumed to lie at the basis of the
development of cCSC.
Keywords Central serous chorioretinopathy . Diffuse leakage . Focal leakage . Fluorescein angiography . Indocyanine green
angiography
Introduction
Central serous chorioretinopathy (CSC) is a chorioretinal dis-
ease characterized by an accumulation of subretinal fluid (SRF)
that often affects the macula [1–3]. Multimodal imaging tech-
niques can provide a detailed assessment of the extent of retinal
and choroidal abnormalities. In CSC, optical coherence tomog-
raphy (OCT) is used to identify the presence of SRF, the
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integrity of the anatomical layers of the retina, and possible
changes in these layers such as outer retinal atrophy and/or
posterior cystoid retinal degeneration [4]. Parameters on SD-
OCT may be helpful in predicting disease course in CSC [5].
SRF accumulation in CSC is the result of fluid leakage
through a disrupted outer blood-retina barrier of the retinal
pigment epithelium (RPE), while the underlying choroidal
dysfunction seems to be a pivotal and probably primary ab-
normality in the pathogenesis of CSC. Therefore, both fluo-
rescein angiography (FA) and indocyanine green angiography
(ICGA) are valuable imaging techniques in the diagnosis, as-
sessment of the disease activity and extent, as well as
informing treatment choices in CSC [6–9]. FA can be used
to detect the location, size, and number of Bhot spots^ of
leakage and the extent of diffuse atrophic RPE alterations
(DARA). ICGA can be performed to evaluate the underlying
choroidal abnormalities [8, 10, 11]. Both FA and ICGA are
therefore used to identify the area(s) for targeted treatment, for
instance with photodynamic therapy (PDT) and high-density
subthreshold micropulse laser (HSML) treatment [7, 12, 13].
In chronic CSC (cCSC), little is known about the clinical
characteristics of patients with different phenotypes such as
focal leakage or diffuse leakage on FA. If differences in the
clinical characteristics and outcome of cCSC patients with
focal leakage or diffuse leakage can be detected, this may also
have prognostic and therapeutic consequences, and may give
clues about potential difference in etiologies between these
groups. The aim of this study is to describe the variety in
abnormalities on FA and ICGA in the affected and fellow
eye, to assess whether FA and ICGA abnormalities are com-
parable, and to compare clinical characteristics when dividing
patients in groups based on focal or diffuse leakage on FA.
Materials and methods
Data from the Bhalf-dose Photodynamic therapy versus high-
density subthreshold micropulse LAser treatment in patients
with chronic CEntral serous chorioretinopathy^ (PLACE) trial
(ClinicalTrials.gov identifier: NCT01797861) was analyzed
[13, 14]. The PLACE trial was conducted from 2013 to
2016 at 5 academic medical centers, located in Leiden (the
Netherlands), Nijmegen (the Netherlands), Cologne
(Germany), Oxford (United Kingdom), and Paris (France).
The study was performed in accordance with the tenets of
the Declaration of Helsinki, and all participating centers
received approval from their respective institutional review
board and ethics committee. Written informed consent was
obtained from all patients.
Patients who received previous CSC treatments (including
oral medication such as eplerenone or spironolactone) or treat-
ment with steroids within 3 months of screening were
excluded. Additional inclusion and exclusion criteria are sum-
marized in Table 1.
Patient demographics, BCVA in Early Treatment of
Diabetic Retinopathy Study (ETDRS) letters, enhanced
depth imaging (EDI) OCT, fundus autofluorescence
(FAF), FA, and ICGA (Heidelberg Engineer ing,
Heidelberg, Germany) were obtained at baseline. Eligible
patients were divided in two groups, based on the leakage
pattern on FA at baseline [15]. The group of patients with
focal leakage had a maximum of 1 hot spot of leakage on
FA. A hot spot of leakage was defined as an increase in the
area of hyperfluorescence between early- and late-phase
FA. Patients with diffuse leakage had either > 1 hot spot
of leakage or a larger area of hyperfluorescent leakage that
could not be linked with a single spot of leakage on the FA
image at 3 min after the start of infusion of fluorescein.
DARA was defined as hyperfluorescent abnormalities on
mid-phase FA [16]. The extent of DARA was divided in
three groups based on their cumulative surface: first, < 1
optic disc diameter; second, between 1 and 5 optic disc
diameters; and the third group with > 5 optic disc diameters
of DARA. The degree of fluorescence on mid-phase ICGA
(at 10 min after the start of infusion) at the location corre-
sponding with the hot spot on FA was categorized in in-
tense hyperfluorescence, intermediate hyperfluorescence,
or absence of hyperfluorescence [17]. Additionally, the size
of the abnormalities on ICGA (< 1 optic disc diameter, 1–5 optic
disc diameters, and > 5 optic disc diameters) was obtained.
Patients were also categorized based on the correspondence of
abnormalities on FA with findings on ICGA. The outcome of
FAF imaging was categorized as either predominantly
hyperautofluorescent, predominantly hypoautofluorescent, or a
combination of hypo- and hyperautofluorescence, based on the
degree of autofluorescence that was most common within the
vascular arcades. Central foveal thickness (CFT) was defined as
the distance between the inner borders of the internal limiting
membrane and the inner border of the ellipsoid zone on SD-
OCT [18]. Subfoveal choroidal thickness (SFCT) was defined
as the distance between the outer border of the RPE layer and the
inner border of the choroid-sclera junction on enhanced depth
imaging SD-OCT. Both CFTand SFCTwere measured with the
build-in caliper in the Heidelberg OCT machine software.
For the first 30 patients, FA and ICGA imaging were
independently assessed by two experienced observers
(EHCvD and TJvR). When there was no consensus, a
third experienced observer (CJFB) had the decisive vote.
An interobserver agreement calculation was performed for
these first 30 patients. Thereafter, all imaging was
assessed by TJvR and discussed with the senior author
(CJFB) if deemed necessary. When ambiguous, the Bdraw
region^ tool in Heidelberg was used to determine the size
of the optic disc and the size of abnormalities on FA and
ICGA.
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Statistical analyses
The statistical analyses were performed with SPSS Statistics
(IBM Corp. version 23.0. Armonk, New York, United States
of America). Independent t test was used to compare contin-
uous variables and Fisher exact tests for categorical variables
between the focal leakage and diffuse leakage groups. After
Bonferroni correction for 40 parameters, P values lower than
0.00125 (0.05/40) were considered to be statistically
significant.
Results
In the PLACE trial, from November 2013 to September 2016,
a total of 309 patients were screened for eligibility. After ap-
plying the inclusion and exclusion criteria, 141 male and 32
female patients could be included in this study. The 173 in-
cluded patients had a mean age of 48.6 ± 8.6 years. The mean
duration from the start of ocular complaints until baseline
study visit was 7.1 ± 4.4 months. At baseline, mean BCVA
was 76.4 ± 9.0 ETDRS letters, mean CFT was 106.6 ±
25.1 μm, and mean SFCTwas 414.7 ± 113.9 μm.
Interobserver agreement
For the first 30 patients that were assessed, the interobserver
agreement of focal versus diffuse disease on FA was 90%.
Cohen’s kappa coefficient was used to assess the interobserver
agreements for focal versus diffuse disease, which was found
to be 0.80. The first observer (TJvR) re-assessed the imaging
of the first 30 patients with regard to focal or diffuse leakage at
6 months after initial assessment. In 97% of the patients, the
categorization was identical to the results of the first assess-
ment. For DARA size on FA (smaller than 1 optic disc diam-
eter, between 1 and 5 optic disc diameters, or larger than 5
optic disc diameters), an intraclass correlation coefficient was
calculated using a two-way mixed model. There was agree-
ment between the two observers in 87% of patients, with an
intraclass correlation coefficient of 0.80.
Clinical characteristics of the focal leakage and diffuse
leakage groups
Sixty-eight patients were categorized as having focal leakage
(focal leakage group) and 105 patients were categorized as
having diffuse leakage on FA (diffuse leakage group). There
were 23 out of 68 patients (33.8%) in the focal leakage group
with a previous CSC episode, and 25 out of 104 patients
(24%) in the diffuse leakage group with a previous episode
of CSC (in 1 patient the information was unavailable), which
was not a statistically significant difference between the
groups (p = 0.162). Characteristics of the patient groups with
focal leakage and diffuse leakage on FA are depicted in Fig. 1.
In the patients with focal leakage on FA, a mean age of 46.8 ±
8.8 years, a mean duration of symptoms until cCSC diagnosis
of 7.3 ± 4.7 months, a mean BCVA of 77.1 ± 8.1 ETDRS let-
ters, a mean CFT of 107.1 ± 21.3 μm, and a mean SFCT of
407.5 ± 114.8 μm were found. CFT could not be measured in
1 patient and SFCT could not be measured in 19 patients, due
to suboptimal quality of EDI-OCT imaging. At the screening
visit, patients with diffuse leakage on FA had a mean age of
49.7 ± 8.2 years, a mean duration of symptoms until cCSC
diagnosis of 7.0 ± 4.2 months, a mean BCVA of 76.0 ± 9.6
ETDRS letters, a mean CFT of 106.2 ± 27.3 μm, and a mean
SFCT of 419.2 ± 113.9 μm, none of which were significantly
different from the focal leakage group after Bonferroni correc-
tion (p = 0.033, p = 0.704, p = 0.440, p = 0.818, p = 0.578, re-
spectively). Because of insufficient EDI-OCT imaging quality
(the scleral border could not be determined), SFCT could not
be obtained in 27 patients with diffuse leakage on FA. There
were no significant differences (p = 0.423) between sex at
Table 1 Inclusion and exclusion
criteria of chronic central serous
chorioretinopathy patients that
were enrolled to this study
Inclusion criteria Exclusion criteria
Male or female cCSC patients ≥ 18 years old Previous treatments for CSC
Visual loss and/or presence of SRF on OCT > 6 weeks Intraretinal edema
Foveal SRF Myopia < − 6 diopters
At least one hyperfluorescent area of leakage on FA
with RPE window defects typical for cCSC
Evidence of another diagnosis that
could explain the vision loss or SRF
Best-corrected visual acuity (BCVA) of > 20/200 in
Snellen equivalent
Continuous or progressive visual loss
or presence of SRF > 18 months
Hyperfluorescent areas on ICGA Currently treated or treated with corticosteroids within
the last 3 months prior to screening visit
Sufficient quality of FA and ICGA imaging Presence of soft drusen or signs of neovascularization
Contraindications to receive FA, ICGA or PDT
(c)CSC (chronic) central serous chorioretinopathy, FA fluorescein angiography, ICGA indocyanine green angiog-
raphy, PDT photodynamic therapy, SRF subretinal fluid
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baseline between the focal leakage group (53 men, 77.9%)
and diffuse leakage group (88 men, 83.8%). In the focal leak-
age group, there were 58 patients (85.3%) with DARA < 1
optic disc diameter, 9 patients (13.2%) with DARA 1–5 optic
disc diameters, and 1 patient (1.5%) with DARA of > 5 optic
disc diameters on FA. In comparison, the diffuse leakage
group consisted of 60 patients (57.1%) with DARA < 1 optic
disc diameter, 35 patients (33.3%) with DARA 1–5 optic disc
diameters, and 10 patients (9.5%) with DARA of > 5 optic
disc diameters (p < 0.001, p = 0.004, and p = 0.052, respec-
tively, compared to the focal leakage group). In the focal leak-
age group, there were 56 patients (82.4%) with foveal DARA,
12 patients (17.6%) with DARAwithin 1 optic disc diameter
from the fovea, and no patients with DARA outside the fovea,
as compared to 91 patients (86.7%), 12 patients (11.4%), and
2 patients (1.9%) with these characteristics in the diffuse leak-
age group, respectively (p = 0.516, p = 0.269, and p = 0.519,
respectively). In the focal leakage group, none of the patients
h a d h y p o f l u o r e s c e n c e o n ICGA , wh i l e m i l d
hyperfluorescence was observed in 6 patients (8.8%), and in-
tense hyperfluorescence was seen in 62 patients (91.2%). In
contrast, the diffuse leakage group consisted of 4 patients
(3.8%) with hypofluorescence on ICGA, 20 patients (19.2%)
with mild hyperfluorescence on ICGA (p = 0.081), and 81
patients (77.1%) with intense hyperfluorescence on ICGA
(p = 0.023, compared to the focal leakage group). The areas
of hyperfluorescent abnormalities on ICGAwere more exten-
sive on FA in 30 of the patients (44.1%) in the focal leakage
group, whereas there were 58 patients (55.2%) in the diffuse
leakage group (p = 0.161). In all other patients, the size of the
area of hyperfluorescent abnormalities on FA and ICGAwas
comparable, with none of the patients showing a smaller area
of hyperfluorescent abnormalities on ICGA as compared to
FA. The autofluorescence description on FAF was
Fig. 1 Multimodal imaging of two chronic central serous
chorioretinopathy (cCSC) patients who were considered to show focal
leakage (a–e) and diffuse leakage (f–j) on fluorescein angiography (FA).
a–e A 51-year-old man with foveal retinal pigment epithelium (RPE)
alterations on fundus photography (a) with a more extensive area of
hyperautofluorescence on fundus autofluorescence (FAF), compared to
the size of the pigment alterations (b). Foveal subretinal fluid with some
hyperreflective subretinal debris was detected on optical coherence
tomography (OCT; c). Both FA (d) and indocyanine green angiography
(ICGA; e) showed a focal leakage spot, indicated by the white arrow. In
addition, hyperfluorescent retinal pigment epithelium alterations are
visible on FA (d). ICGA shows a more extensive area of
hyperfluorescence compared to FA (e). f, g A 52-year-old man
categorized as having diffuse leakage. RPE changes are visible on
fundus photography (f). Both hyper- and hypoautofluorescent
abnormalities are present on FAF (g). Foveal subretinal fluid is present
on OCT, as well as some hyperreflective deposits and RPE irregularities
(h). FA shows both a focal leakage spot (white arrow) and an area of
diffuse hyperfluorescent leakage (within the dashed borders; i). Multiple
areas of hyperfluorescence typical of cCSC are visible on ICGA (j),
which are more extensive than the abnormalities on FA
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predominantly hypoautofluorescent in 27 patients (39.7%),
predominantly hyperautofluorescent in 17 patients (25.0%),
and both hyper- and hypoautofluorescent in 24 patients
(35.3%) in the focal leakage group, while this was the case
in 28 patients (26.9%), 29 patients (27.9%), and 47 patients
(45.2%) in the diffuse leakage group, respectively. There were
no significant differences between the degree of autofluores-
c ence on FAF in pa t i en t s w i th p r edominan t l y
hypoautofluorescence (p = 0.095), predominantly
hyperautofluorescence (p = 0.727), and both hyper- and
hypoautofluorescence (p = 0.209) on FAF, between the focal
and diffuse leakage groups.
Characteristics of the fellow eye on multimodal
imaging
The characteristics of the fellow eye for both the focal leakage
and diffuse leakage group are shown in Table 2. SRF in the
fellow eye was present in 11 patients (16.2%) in the focal
leakage group, as compared to 30 patients (29.1%) in the
diffuse leakage group (p = 0.067). In the focal leakage group,
there were 33 patients (49.3%) without DARA in the fellow
eye on FA, 24 patients (35.8%) with DARA < 1 optic disc
diameter, 9 patients (13.4%) with DARA between 1 and 5
optic disc diameters, and 1 patient (1.5%) with DARA > 5
optic disc diameters. In comparison, the diffuse leakage group
consisted of 29 patients (28.2%) without DARA in the fellow
eye on FA (p = 0.009), 53 patients (51.5%) with DARA < 1
optic disc diameters (p = 0.060), 14 patients (13.6%) with
DARA between 1 and 5 optic disc diameters (p > 0.999),
and 7 patients (6.8%) with DARA > 5 optic disc diameters
(p = 0.151). There were no statistically significant differences
between the focal and diffuse leakage group regarding the
FAF characteristics (Table 2).
Discussion
In this study, cCSC patients were divided into two categories,
based on early-phase FA abnormalities: focal leakage was
defined as a maximum of one hot spot of leakage, whereas
the diffuse leakage group comprised patients with either mul-
tiple hot spots of leakage or a larger area of leakage. We
hypothesized that more severe and extensive disease would
be present in the diffuse leakage group, with a potentially
different prognosis and treatment response outcome. In our
study, abnormalities on ICGA were never smaller than on
FA in all patients in both groups. Most of the patients in both
groups had multifocal hyperfluorescent abnormalities on
ICGA outside the area of the hotspot on FA. No significant
differences in BCVA, CFT, and SFCT between the focal and
diffuse leakage group were found. The fellow eye of patients
with diffuse leakage on FA was more often affected by SRF,
although this difference did not reach the threshold of statisti-
cal significance.
In both the focal and the diffuse leakage group, none of the
patients had a smaller area of abnormalities on ICGA com-
pared to FA, which corresponds to findings in previous studies
[6, 19]. In addition, multifocal areas of hyperfluorescence on
ICGA outside the zone of leakage on FAwere often present in
both groups. ICGA is primarily used to evaluate the status of
the choroid, while FA can reveal both DARA and hot spots of
fluorescein leakage [10, 20]. For CSC, this suggests that cho-
roidal abnormalities are generally more extensive than abnor-
malities of the RPE. Chronic CSC may arise as chronic cho-
roidal thickening (pachychoroid) and dysfunction, such as
hyperpermeability and congestion, gradually causing RPE
damage. This pachychoroid and associated choroidal dysfunc-
tion may lead only to DARAwithout SRF leakage, which is
then compatible with pachychoroid pigment epitheliopathy,
which can be regarded as the forme fruste of CSC [21]. As a
complication, the RPE outer blood-retina barrier can be dam-
aged to such a degree that SRF leaks through an RPE defect,
causing active SRF leakage in CSC. Since choroidal abnor-
malities on ICGA extend further than those on FA, guided
treatment would underestimate the extent of the underlying
disease and may lead to suboptimal treatment efficacy with a
higher risk of recurrences due to inadequate treatment area
coverage. ICGA-guided treatment may therefore be preferable
for optimal treatment efficacy [7, 13]. The observation that
abnormalities on ICGA are generally at least as extensive as
the RPE abnormalities on FA may also explain why PDT,
which primarily targets the dysfunctional choroid, is more
effective in achieving a complete resolution of SRF and leads
to a better functional outcome as compared to HSML in the
PLACE trial [13].
Patients with an absence of hyperfluorescent abnormalities
on ICGA are less likely to respond favorably to PDT treatment
[22, 23]. Despite the fact that abnormalities on ICGA are often
more widespread compared to FA, strongly suggesting that
choroidal changes are underlying in CSC, chronic damage to
the RPEmay also be of importance in the pathogenesis of SRF
leakage even if choroidal hyperfluorescence and leakage be-
come less pronounced in ICGAwith time.
BCVA, CFT, and SFCT did not differ significantly between
the focal and diffuse leakage groups, which may indicate that
patients with diffuse leakage do not necessarily have a func-
tionally more severe phenotype in comparison to patients with
focal leakage [16]. The primary pathophysiological mecha-
nism in CSC could thus be the same, resulting in dysfunction
of the choroid and RPE, regardless of the CSC subtypes.
Despite the fact that this is the first phenotypic study on
cCSC based on a large prospective multimodal imaging
dataset, there are limitations to this study. The focal leakage
and diffuse leakage categories that were designed for this
study may be somewhat arbitrary. However, these categories
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were based on the results of other studies, clinical experience,
and observations of two independent graders [2, 10, 15, 24].
In conclusion, abnormalities on FA appear to be of similar
size or larger on ICGA, in both focal and diffuse leakage
groups, which may indicate primary dysfunction of the cho-
roid. No significant differences in BCVA, CFT, and SFCT
were found between cCSC with focal versus diffuse leakage,
which may suggest that the type of leakage is not necessarily
associated with a big difference in functional severity of dis-
ease. Our findings also indicate that these subgroups are likely
to share the same pathophysiologic background. Further stud-
ies are needed to assess if there are differences in response to
treatment and long-term outcome between these cCSC
subgroups.
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Table 2 Demographics and characteristics of chronic central serous chorioretinopathy patients in the focal leakage and diffuse leakage group at
presentation
Affected eye Focal leakage
(n = 68)
Diffuse leakage
(n = 105)
Mean ± SD Mean ± SD p value
Age at screening (years) 46.9 ± 8.8 49.7 ± 8.3 0.033
Duration of symptoms until cCSC diagnosis (months) 7.3 ± 4.7 7.0 ± 4.2 0.704
BCVA in ETDRS letters 77.1 ± 8.1 76.0 ± 9.6 0.440
CFT (μm) 107.1 ± 21.3 106.2 ± 27.3 0.818
SFCT (μm) 407.5 ± 114.8 419.2 ± 113.9 0.578
Number (%) Number (%)
Sex Male 53 (77.9%) 88 (83.8%) 0.423
DARA on FA < 1 optic disc diameter 58 (85.3%) 60 (57.1%) < 0.001*
1–5 optic disc diameter 10 (14.7%) 45 (42.9%) 0.004
> 5 optic disc diameter 1 (1.5%) 10 (9.5%) 0.052
Location of DARA Fovea 56 (82.4%) 90 (86.5%) 0.516
Within 1 optic disc diameter of the
fovea
12 (17.6%) 12 (11.5%) 0.269
Outside the fovea 0 (0.0%) 2 (1.9%) 0.519
Degree of hyperfluorescence on ICGA Hypofluorescence 0 (0.0%) 4 (3.8%) 0.154
Mild hyperfluorescence 6 (8.8%) 20 (19.2%) 0.081
Intense hyperfluorescence 62 (91.2%) 80 (76.9%) 0.023
Hyperfluorescent areas on ICGA outside of the leakage spot
on FA
Yes 48 (70.6%) 91 (87.5%) 0.009
Comparability of the size of the abnormalities on FA and
ICGA
Larger on ICGA 30 (44.1%) 58 (55.2%) 0.161
Degree of autofluorescence on FAF Predominantly hypoautofluorescent 27 (39.7%) 28 (26.9%) 0.095
Predominantly hyperautofluorescent 17 (25.0%) 29 (27.9%) 0.727
Both hyper- and hypoautofluorescent 24 (35.3%) 47 (45.2%) 0.209
BCVA best-corrected visual acuity, CFT central foveal thickness, SFCT subfoveal choroidal thickness,DARA diffuse atrophic retinal pigment epithelium
alterations, FA fluorescein angiography, FAF fundus autofluorescence, ICGA indocyanine green angiography, RPE retinal pigment epithelium, SD
standard deviation
*P values < 0.00125 were considered to be statistically significant
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